These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 11327199)
21. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Hsu A; Granneman GR; Bertz RJ Clin Pharmacokinet; 1998 Oct; 35(4):275-91. PubMed ID: 9812178 [TBL] [Abstract][Full Text] [Related]
22. Long-term pharmacokinetics of amprenavir in combination with delavirdine in HIV-infected children. Engelhorn C; Hoffmann F; Kurowski M; Stocker H; Kruse G; Notheis G; Belohradsky BH; Wintergerst U AIDS; 2004 Jul; 18(10):1473-5. PubMed ID: 15199327 [TBL] [Abstract][Full Text] [Related]
23. [Non-nucleoside reverse transcriptase inhibitors]. Joly V; Yeni P Ann Med Interne (Paris); 2000 Jun; 151(4):260-7. PubMed ID: 10922953 [TBL] [Abstract][Full Text] [Related]
24. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens. Joly V; Descamps D; Yeni P AIDS Rev; 2002; 4(3):128-39. PubMed ID: 12416447 [TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. Borin MT; Chambers JH; Carel BJ; Gagnon S; Freimuth WW Clin Pharmacol Ther; 1997 May; 61(5):544-53. PubMed ID: 9164416 [TBL] [Abstract][Full Text] [Related]
27. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens. Patel N; Abdelsayed S; Veve M; Miller CD Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025 [TBL] [Abstract][Full Text] [Related]
28. Effect of fluconazole on the steady-state pharmacokinetics of delavirdine in human immunodeficiency virus-positive patients. Borin MT; Cox SR; Herman BD; Carel BJ; Anderson RD; Freimuth WW Antimicrob Agents Chemother; 1997 Sep; 41(9):1892-7. PubMed ID: 9303380 [TBL] [Abstract][Full Text] [Related]
29. [Role of etravirine in combination antiretroviral therapy]. Domingo P Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():46-51. PubMed ID: 20116628 [TBL] [Abstract][Full Text] [Related]
35. Multiple-Dose Pharmacokinetics of Delavirdine Mesylate and Didanosine in HIV-Infected Patients. Morse GD; Cohn SE; Shelton MJ; Greisberger C; Cox SR; Della-Coletta AA; Freimuth WW; Reichman RC Clin Drug Investig; 2003; 23(5):323-8. PubMed ID: 17535044 [TBL] [Abstract][Full Text] [Related]
36. Interactions between antiretrovirals and antineoplastic drug therapy. Antoniou T; Tseng AL Clin Pharmacokinet; 2005; 44(2):111-45. PubMed ID: 15656694 [TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors. Ma Q; Okusanya OO; Smith PF; Dicenzo R; Slish JC; Catanzaro LM; Forrest A; Morse GD Expert Opin Drug Metab Toxicol; 2005 Oct; 1(3):473-85. PubMed ID: 16863456 [TBL] [Abstract][Full Text] [Related]
38. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial. MacArthur RD; Novak RM; Peng G; Chen L; Xiang Y; Hullsiek KH; Kozal MJ; van den Berg-Wolf M; Henely C; Schmetter B; Dehlinger M; ; Lancet; 2006 Dec; 368(9553):2125-35. PubMed ID: 17174704 [TBL] [Abstract][Full Text] [Related]
39. Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection. Morse GD; Fischl MA; Shelton MJ; Cox SR; Driver M; DeRemer M; Freimuth WW Antimicrob Agents Chemother; 1997 Jan; 41(1):169-74. PubMed ID: 8980774 [TBL] [Abstract][Full Text] [Related]